Matching Items (118)
Filtering by
- Member of: Barrett, The Honors College Thesis/Creative Project Collection
- Status: Published
Description
Glioblastoma multiforme (GBM) is an aggressive malignant brain tumor with a median prognosis of 14 months. Human hairless protein (HR) is a 130 kDa nuclear transcription factor that plays a critical role in skin and hair function but was found to be highly expressed in neural tissue as well. The expression of HR in GBM tumor cells is significantly decreased compared to the normal brain tissue and low levels of HR expression is associated with shortened patient survival. We have recently reported that HR is a DNA binding phosphoprotein, which binds to p53 protein and p53 responsive element (p53RE) in vitro and in intact cells. We hypothesized that HR can regulate p53 downstream target genes, and consequently affects cellular function and activity. To test the hypothesis, we overexpressed HR in normal human embryonic kidney HEK293 and GBM U87MG cell lines and characterized these cells by analyzing p53 target gene expression, viability, cell-cycle arrest, and apoptosis. The results revealed that the overexpressed HR not only regulates p53-mediated target gene expression, but also significantly inhibit cell viability, induced early apoptosis, and G2/M cell cycle arrest in U87MG cells, compared to mock groups. Translating the knowledge gained from this research on the connections between HR and GBM could aid in identifying novel therapies to circumvent GBM progression or improve clinical outcome.
ContributorsBrook, Lemlem Addis (Author) / Blattman, Joseph (Thesis director) / Hsieh, Jui-Cheng (Committee member) / Goldstein, Elliott (Committee member) / Harrington Bioengineering Program (Contributor) / School of Social Transformation (Contributor) / Barrett, The Honors College (Contributor)
Created2018-05
Description
Mr. Green has stage 4 prostate cancer which has spread to the bones and liver and has become resistant to radiation and standard chemotherapy treatment. After 3 rounds of chemotherapy, his primary oncologist recommends that he participate in a clinical trial. He went to Dr. Red at the Saguaro Clinic after reading on the internet about a new Phase 1 clinical trial that the clinic is hosting, which is designed to target a specific receptor called AB-111 that may be present in malignant prostate, cervical, ovarian, and breast cells. After signing consent and completing the blood screens in the morning at the clinic, Mr. Green is told his liver enzymes are too high and the ranges specified in the protocol prohibit him from enrolling. Mr. Green is noticeably affected and distressed at this news, and Dr. Red recommends end-of-life care. Behind the scenes, this event is noted on official medical documents and trial study rosters as a "screen fail." This narrative, while fictional, is realistic because similar events occur in cancer clinical trial sites on a regular basis. I look at the inner "world" and mental journey of possible clinical trial candidates as they seek out information about clinical trials and gain understanding of their function \u2014 specifically in the context of Phase 1 cancer clinical trials. To whom is the language of the term "screen failure" useful? How does excluding individuals from clinical trials protect their health and does the integrity of the trial data supersede the person's curative goals? What is the message that cancer patients (potential research subjects) receive regarding clinical trials from sources outside their oncologists?
ContributorsMcKane, Alexandra (Author) / Maienschein, Jane (Thesis director) / Ellison, Karin (Committee member) / Foy, Joseph (Committee member) / Barrett, The Honors College (Contributor)
Created2013-12
Description
A coincidence reporter construct, consisting of the p21-promoter and two luciferase genes (Firefly and Renilla), was constructed for the screening of drugs that might inhibit Olig2's tumorigenic role in glioblastoma. The reporter construct was tested using an Olig2 inhibitor, HSP990, as well as short hairpin RNA targeting Olig2. Further confirmatory analysis is needed before the reporter cell line is ready for high-throughput screening at the NIH and lead compound selection.
ContributorsCusimano, Joseph Michael (Author) / LaBaer, Joshua (Thesis director) / Mangone, Marco (Committee member) / Mehta, Shwetal (Committee member) / Barrett, The Honors College (Contributor) / Department of Chemistry and Biochemistry (Contributor)
Created2014-05
Description
Glioblastoma Multiforme (GBM) is an aggressive and deadly form of brain cancer with a median survival time of about a year with treatment. Due to the aggressive nature of these tumors and the tendency of gliomas to follow white matter tracks in the brain, each tumor mass has a unique growth pattern. Consequently it is difficult for neurosurgeons to anticipate where the tumor will spread in the brain, making treatment planning difficult. Archival patient data including MRI scans depicting the progress of tumors have been helpful in developing a model to predict Glioblastoma proliferation, but limited scans per patient make the tumor growth rate difficult to determine. Furthermore, patient treatment between scan points can significantly compound the challenge of accurately predicting the tumor growth. A partnership with Barrow Neurological Institute has allowed murine studies to be conducted in order to closely observe tumor growth and potentially improve the current model to more closely resemble intermittent stages of GBM growth without treatment effects.
ContributorsSnyder, Lena Haley (Author) / Kostelich, Eric (Thesis director) / Frakes, David (Committee member) / Barrett, The Honors College (Contributor) / School of Mathematical and Statistical Sciences (Contributor) / Harrington Bioengineering Program (Contributor)
Created2014-05
Description
Abstract Molecular Engineering of Novel Polymeric Agents for Targeted Cancer Gene Therapy Dana Matthews Cancer gene cell therapy is a strategy that involves the administration of genes for correcting the effect of mutated cancer cells in order to induce tumor cell death. In particular, genes that encode for pro-apoptotic proteins can result in death of tumor cells. Prostate cancer is a very common cancer among males in America, and as highly destructive chemotherapy and radiation are generally the only treatments available once the cancer has metastasized, there is a need for the development of treatments that can specifically target and kill prostate cancer cells, while demonstrating low toxicity to other tissue. This experiment will attempt to create such a treatment through gene therapy techniques. The parallel synthesis and DNA binding affinity assay utilized in these experiments have produced a polymer that surpasses pEI-25, a gene delivery polymer standard, in both transfection efficacy and low cytotoxicity and trafficking of polyplexes in the cell, and finding methods to increase the transfection efficacy and specificity of polyplexes for PC3-PSMA cells.
ContributorsMatthews, Dana (Author) / Rege, Kaushal (Thesis director) / Linton, Rebecca (Committee member) / Huang, Huang-Chial (Committee member) / Barrett, The Honors College (Contributor)
Created2008-12
Description
This paper seeks to put a spotlight on much that is wrong in the United States with cancer drug development, pricing, marketing and outcomes. Roche Pharmaceutical's cancer drug, Avastin will be used as an example to highlight these issues. Drug patents, Medicare policies, weak metrics of efficacy and ceaseless demand—allow drug manufacturers to price their oncology treatments as they choose, regardless of results, and with virtually no competition, avenue or institution that serves to lower prices in the United States. Avastin will be established as an oncology drug that is overpriced and poorly evaluated based on its effectiveness. Facts, opinions and study analytics will be offered (from industry experts, insiders, doctors and scientists) that in almost all cases show that patients treated with Avastin receive marginal benefit. Allowing Medicare to negotiate drug prices with manufacturers, reducing conflicts of interest for doctors, setting research & development investment requirements and creating more relevant clinical metrics for use in FDA approvals would help reduce the financial burden on cancer patients and taxpayers.
ContributorsTrettin, Michael William (Author) / Simonson, Mark (Thesis director) / Budolfson, Arthur (Committee member) / Department of Finance (Contributor) / Barrett, The Honors College (Contributor)
Created2017-05
Description
Through a standpoint feminist perspective (Harding 2009) I conducted a situational analysis (Clarke, 2015) that examined academic literature and cancer support discussion boards (DBs) to identify how Western biomedicine, specifically oncology, can integrate complementary and alternative medicine (CAM) to improve cancer treatment in children. The aims of this project were: 1) to identify the CAM treatments that are being used to alleviate the side effects from oncological treatments and/or treat pediatric cancers; 2) to compare the subjective experience of CAM to Western biomedicine of cancer patients who leave comments on Group Loop, Cancer Compass and Cancer Forums, which are online support groups (N=20). I used grounded theory and situational mapping to analyze discussion threads. The participants identified using the following CAM treatments: herbs, imagery, prayer, stinging nettle, meditation, mind-body therapies and supplements. The participants turned to CAM treatments when their cancer was late-stage or terminal, often as an integrative and not exclusively to treat their cancer. CAM was more "effective" than biomedical oncology treatment at improving their overall quality of life and functionality. We found that youth on discussion boards did not discuss CAM treatments like the adult participants, but all participants visited these sites for support and verification of their cancer treatments. My main integration recommendation is to combine mind-body CAM therapies with biomedical treatment. This project fills the gap in literature that ignores the ideas of vulnerable populations by providing the experiences of adult and pediatric cancer patients, and that of their families. It is applicable to areas of the social studies of medicine, patient care, and families suffering from cancer. KEYWORDS: Cancer; Complementary and Alternative Medicine; Situational Analysis; Standpoint Feminism
ContributorsEsposito, Sydney Maria (Author) / Martinez, AirÃÂn (Thesis director) / Hruschka, Daniel (Committee member) / School of Human Evolution and Social Change (Contributor) / Barrett, The Honors College (Contributor)
Created2016-12
Description
Cancer rates in our nearest relatives are largely unknown. Comparison of human cancer rates with other primates should help us to understand the nature of our susceptibilities to cancer. Data from deceased primates was gathered from 3 institutions, the Duke Lemur Center, San Diego Zoo, and Jungle Friends primate sanctuary. This data contained over 400 unique individuals across 45 species with information on cancer incidence and mortality. Cancer incidence ranged from 0-71% and cancer mortality ranged from 0-67%. We used weighted phylogenetic regressions to test for an association between life history variables (specifically body mass and lifespan) and cancer incidence as well as mortality. Cancer incidence did not correlate with both body mass and lifespan (p>.05) however, cancer mortality did (p<.05). However, it is uncertain if the variables can be used as reliable predictors of cancer, because the data come from different organizations. This analysis presents cancer incidence rates and cancer mortality rates in species where it was previously unknown, and in some primate species, is surprisingly high. Microcebus murinus(grey mouse lemur) appear to be particularly vulnerable to cancer, mostly lymphomas. Further studies will be required to determine the causes of these vulnerabilities.
ContributorsWalker, William Charles (Author) / Maley, Carlo (Thesis director) / Boddy, Amy (Committee member) / School of Life Sciences (Contributor) / Barrett, The Honors College (Contributor)
Created2017-05
Description
Cancer is a disease that has no bias based on race, gender, sexuality, socioeconomic status, or religious beliefs. Millions upon millions of people are affected every day by this disease in many different ways. In order to show support and raise funds for these people to help with treatment costs, housing, and much more American Cancer Society created and event called Relay for Life. Relay for Life is an event that many people may describe as a walk-a-thon fundraiser, but to those who have had a personal experience with cancer they understand that Relay is much more. Relay for Life is more than a fundraiser; it is an event that brings hope, love, and care into a community. Many people across the country show up to a Relay event to hear the success stories of those who are in remission, show support for their family and friends who are still fighting, and simply volunteer in order to further remember those that they lost to cancer.
The impacts that Relay for Life supplies go beyond monetary value and branch into the world of emotional and mental value. The stories that you hear from cancer patients, caregivers, survivors, friends, and family all show the appreciation for this event even in the smallest of communities. Looking at the Relay for Life website you can see the thousands of submissions detailing exactly why that individual participates in this event. You can read stories of sorrow, drive, friendships that have formed, and hope that has sprouted because of Relay for Life. An event such as this that celebrates the fight and works to give the world more birthdays truly empowers its participants to make a difference and make a connection with each other.
In this project, I set out to reveal the importance of Relay for Life that can be seen and heard through everyone who participates across the nation. It is important to take both personal experience and monetary value into account when looking at how Relay has had a positive impact on the lives of those affected by cancer, but when looking at the broad picture it becomes obvious how this event means more than money.
The impacts that Relay for Life supplies go beyond monetary value and branch into the world of emotional and mental value. The stories that you hear from cancer patients, caregivers, survivors, friends, and family all show the appreciation for this event even in the smallest of communities. Looking at the Relay for Life website you can see the thousands of submissions detailing exactly why that individual participates in this event. You can read stories of sorrow, drive, friendships that have formed, and hope that has sprouted because of Relay for Life. An event such as this that celebrates the fight and works to give the world more birthdays truly empowers its participants to make a difference and make a connection with each other.
In this project, I set out to reveal the importance of Relay for Life that can be seen and heard through everyone who participates across the nation. It is important to take both personal experience and monetary value into account when looking at how Relay has had a positive impact on the lives of those affected by cancer, but when looking at the broad picture it becomes obvious how this event means more than money.
ContributorsTrisko, Rebecca Lynn (Author) / Roen, Duane (Thesis director) / Wales, Anna (Committee member) / Division of Teacher Preparation (Contributor, Contributor) / Barrett, The Honors College (Contributor)
Created2019-05
Description
The human hairless gene (HR) encodes a 130 kDa transcription factor that is primarily expressed in the brain and skin. In the promoter and 5'-untranslated regions (5'-UTR) of HR, there are three putative consensus p53 responsive elements (p53RE). p53 is a tumor suppressor protein that regulates cell proliferation, apoptosis, and other cell functions. The p53 protein, a known tumor suppressor, acts as a transcription factor and binds to DNA p53REs to activate or repress transcription of the target gene. In general, the p53 binding sequence is 5'-RRRCWWGYYY-3' where W is A or T, and R and Y are purines or pyrimidines, respectively. However, even if the p53 binding sequence does not match the consensus sequence, p53 protein might still be able to bind to the response element. The intent of this investigation was to identify and characterize the p53REs in the promoter and 5'-UTR of HR. If the three p53REs (p53RE1, p53RE2, and p53RE3) are functional, then p53 can bind there and might regulate HR gene expression. The first aim for this thesis was to clone the putative p53REs into a luciferase reporter and to characterize the transcription of these p53REs in glioblastoma (U87 MG) and human embryonic kidney (HEK293) cell lines. Through the transactivation assay, it was discovered that p53REs 2 and 3 were functional in HEK293, but none of the response elements were functional in U87 MG. Since p53 displayed a different regulatory capacity of HR expression in HEK293 and U87 MG cells, the second aim was to verify whether the p53REs are mutated in GBM U87 MG cells by genomic DNA sequencing.
ContributorsMaatough, Anas (Author) / Neisewander, Janet (Thesis director) / Hsieh, Jui-Cheng (Committee member) / Goldstein, Elliott (Committee member) / School of Life Sciences (Contributor) / School of Historical, Philosophical and Religious Studies (Contributor) / Barrett, The Honors College (Contributor)
Created2018-05